Diagnostic and Management Strategies for Mitral Regurgitation

Clinical Assessment

The American College of Cardiology recommends that the optimal approach to mitral regurgitation requires accurate assessment of etiology, severity, and hemodynamic consequences, followed by appropriate medical therapy or timely surgical/percutaneous intervention based on symptoms, ventricular function, and patient risk factors 1, 2
The classic finding in primary MR is a holosystolic murmur best heard at the apex with radiation to the axilla 3
Presence of a diastolic filling complex usually indicates significant regurgitant volume and severe MR 1
Symptoms may be absent or subtle even in severe MR due to enhanced left atrial compliance 1
Key symptoms include exertional dyspnea, fatigue, and palpitations 1

The European Heart Journal states that transthoracic echocardiography is the primary diagnostic tool for assessing MR etiology, mechanism, and severity 4
Key parameters to evaluate include valve morphology and mechanism of regurgitation, quantitative measures, left ventricular size and function, and left atrial size and pulmonary artery pressure 4, 5, 6
Transesophageal echocardiography is indicated when TTE is suboptimal or to better define valve anatomy before intervention 1
Cardiac MRI is valuable for assessing LV/RV size and function, mitral annular dimensions, and quantifying regurgitation when echocardiographic findings are inconclusive 4

The European Heart Journal recommends that surgery is indicated for symptomatic patients with severe primary MR 6, 5
Surgery is also indicated in asymptomatic patients with severe primary MR when LVEF <60% or LVESD ≥40 mm, pulmonary hypertension, or new-onset atrial fibrillation 6, 4
Mitral valve repair is strongly preferred over replacement when technically feasible 6, 5
The European Heart Journal suggests that transcatheter edge-to-edge repair may be considered in symptomatic patients with severe primary MR who are at high or prohibitive surgical risk 7
Guideline-directed medical therapy is mandatory as the first step in management of secondary MR, including ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and sacubitril/valsartan in appropriate patients 7, 5

The American College of Cardiology recommends that patients with moderate MR should have clinical evaluation every 6-12 months with annual echocardiography, while patients with severe MR should have clinical evaluation every 6 months with annual echocardiography 5